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Abstract
Purpose—Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The 
association between endocrine therapy and common pelvic floor disorders including urinary 
incontinence has rarely been evaluated. We examined urogenital and sexual side effects among 
women with a breast cancer diagnosis, comparing endocrine therapy users to nonusers.
Methods—Urogenital and sexual symptoms were self-reported during the enrollment interview 
within the University of North Carolina Cancer Survivorship Cohort. Tumor characteristics and 
endocrine therapy use were collected from medical and prescription records. We calculated 
multivariable prevalence ratios (PR) and 95 % confidence intervals (CI) for the association of 
endocrine therapy (versus no endocrine therapy) and urinary incontinence, overall and by therapy 
type (tamoxifen or aromatase inhibitors). PROMIS Sexual Function and Satisfaction domain 
scores were compared across endocrine therapy groups.
Results—Among the 548 women with a breast cancer diagnosis, 49 % received endocrine 
therapy. Overall, 18 % of women reported urinary incontinence symptoms. We observed no 
association between urinary incontinence and endocrine therapy use overall (PR = 0.97; 95 % CI 
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0.67, 1.43), tamoxifen (PR = 1.20; 95 % CI 0.74, 1.96), or aromatase inhibitors (PR = 0.89; 95 % 
CI 0.55, 1.42), compared to no use. Approximately 55 % of women were sexually active. Sexual 
function scores did not vary according to endocrine therapy use, although urinary incontinence 
was associated with lower satisfaction scores (p = 0.05).
Conclusions—Our findings demonstrate a high prevalence of urinary incontinence after breast 
cancer diagnosis similar to the overall prevalence in older U.S. women, and this did not vary 
strongly according to use of endocrine therapy.
Keywords
Endocrine therapy; Cancer survivors; Patient-reported outcomes; Urinary incontinence; Sexual 
function
Background
Breast cancer is the most frequently diagnosed cancer in women in the USA, with an 
expected 231,840 new cases of invasive breast cancer to have been diagnosed in 2015 [1]. 
Long-term survival following a breast cancer diagnosis is nearly 90 % [2], making the health 
and well-being of the more than 3 million breast cancer survivors living in the USA a public 
health priority [3].
Adjuvant endocrine therapy is indicated for breast cancer patients with hormone receptor-
positive invasive breast cancers, which comprise approximately 75 percent of cases overall 
[3]. Premenopausal women with hormonally responsive tumors are treated with tamoxifen in 
the adjuvant setting; postmenopausal women have the additional option of using aromatase 
inhibitors (AIs) for endocrine therapy [4]. Endocrine therapies have been associated with the 
onset or exacerbation of menopausal symptoms and can cause urogenital side effects 
including vaginal dryness, incontinence, and painful intercourse [5]. Evidence suggests that 
AIs may be more strongly associated with sexual function symptoms than tamoxifen due to 
their systemic anti-estrogenic effects. In contrast, tamoxifen can act both as a pro- or anti-
estrogen, depending on the tissue [6–8].
Endocrine therapy may also impact the prevalence of common conditions such as urinary 
incontinence by altering the pelvic floor, but little research exists to address this possibility. 
In the USA, 15–20 % of women over 50 years old report experiencing urinary incontinence 
symptoms [9, 10]. Adult cancer survivors, including survivors of breast cancer, have been 
shown to be more likely to report urinary incontinence than those without a history of cancer 
[11]. Many breast cancer survivors may be faced with both age-related and potential 
endocrine therapy-related increases in pelvic floor disorders, including sexual dysfunction; 
however, limited data exist regarding these issues [12–15]. As the breast cancer survivor 
population continues to grow, addressing therapy side effects that contribute to health-related 
quality of life has become a key concern. To examine the association between endocrine 
therapy use and incident urinary incontinence and sexual dysfunction, we analyzed data 
from the University of North Carolina at Chapel Hill (UNC) Cancer Survivorship Cohort.
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Methods
Study population
The UNC Cancer Survivorship Cohort is an ongoing registry of well-characterized cancer 
patients that integrates clinical, epidemiological, and interview data with correlated biologic 
specimens including DNA and tumor tissue. Patients included in this study were recruited 
through UNC Health Care oncology outpatient clinics from August 2010 to August 2015. 
Eligibility criteria for enrollment in the UNC Cancer Survivorship Cohort include: ages 18 
years or older; a North Carolina mailing address; and English or Spanish proficiency. All 
participants provided informed consent in either English or Spanish. This project was 
reviewed and approved by the Human Research Protections Program (IRB Number: 
09-0605) at UNC Chapel Hill.
For this analysis, patients were further restricted to women with a pathologically confirmed 
diagnosis of stage 0–3 breast cancer who were diagnosed or treated in the UNC Health Care 
system and who completed a baseline questionnaire. We further excluded participants who 
did not have timing information on the start of their endocrine therapy (n = 7) and women 
whose baseline questionnaire was recorded prior to their diagnosis date (n = 3). When 
analyzing urinary incontinence outcomes, we further excluded women who reported having 
urinary incontinence prior to breast cancer diagnosis (n = 80) to exclude prevalent cases. 
After these exclusions, 468 women contributed data to our urinary incontinence analysis and 
548 women contributed to the analysis of sexual function (Fig. 1).
Data collection
Self-reported demographics including age, race/ethnicity, employment, education and 
marital status were obtained at enrollment. The baseline interview was completed by trained 
staff using a computer-assisted telephone interview software tool. The interview took 
approximately 1 h, during which participants responded to both general (45 min) and cancer-
specific (15 min) survey questions, including the patient’s health history, lifestyle, health 
care, and health-related quality of life indicators.
Exposure assessment
Endocrine therapy drugs were obtained from one of two electronic medical record databases: 
the UNC Health Care pharmacy prescription database and the patient’s self-reported 
medication list. When the pharmacy prescription database and the patient’s self-reported 
medication list were not concordant (22 %), medical records were manually abstracted by a 
blinded certified tumor registrar to correctly classify patients’ endocrine therapy status. 
Endocrine therapy was classified in this analysis as use versus nonuse prior to the baseline 
questionnaire and further classified as use of tamoxifen, AIs, or multiple drugs. For the 
urinary incontinence analysis, women who reported the onset of incontinence symptoms 
after breast cancer diagnosis but prior to endocrine therapy initiation were analyzed as 
nonusers.
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Outcome assessment
Urinary incontinence was defined by participant interview responses to the question “How 
often do you leak urine?” Possible responses were never, about once a week or less, two or 
three times a week, about once a day, several times a day, or all the time. We defined never 
versus any self-reported leakage to indicate urinary incontinence. Stress incontinence was 
defined as leakage with coughing or sneezing or physical activity/exercise. Urgency 
incontinence was defined as leakage before reaching the toilet or when sleeping. Participants 
were also asked “In what month and year did you first start to leak urine? (MM/YYYY),” 
and these responses were used to estimate the timing of urinary incontinence.
The PROMIS Sexual Function and Satisfaction Measures Brief Profile (SexFS) provides 
scores on seven different subdomains of sexual function, including interest in sexual activity, 
vaginal discomfort, lubrication, orgasm, and global satisfaction with sex life. Responses to 
this questionnaire were used to create a raw summed score for each question in a given 
subdomain and then translated to a standardized T-score. For the subdomains of global 
satisfaction with sex life, interest in sexual activity and lubrication, higher scores indicate 
better sexual health outcomes. The vaginal discomfort subdomain is scored so that higher 
scores indicate more negative sexual health outcomes (i.e., more discomfort) [16, 17]. 
Minimally important differences in domain scores were defined as half the standard 
deviation of domain score means [18]. This questionnaire has been validated in cancer 
populations [16].
Statistical analysis
Frequencies and proportions of demographic and clinical characteristics were generated by 
endocrine therapy status (yes/no) and type (tamoxifen or AI). Few participants (n = 20, 
4.3 %) switched between tamoxifen and AIs and were excluded from analyses. Continuous 
variables such as age, time since diagnosis, and body mass index (BMI) were categorized 
into clinically meaningful groupings. Domain scores from the SexFS questionnaire were 
summarized by estimating means and standard deviations.
Prevalence ratios (PR) and 95 % confidence intervals (CI) estimates were calculated using a 
Poisson distribution with robust standard errors to approximate the binomial distribution 
[19]. Covariates were selected based on expert opinion and the scientific literature on 
endocrine therapy use, urinary incontinence, and sexual function and included for age, time 
since diagnosis, race, parity, smoking status, hysterectomy history, and BMI.
To analyze the PROMIS sexual function measures, we estimated adjusted means using 
generalized linear models for continuous dependent variables. Each domain score 
(satisfaction, interest, vaginal discomfort, and lubrication) was evaluated as a continuous 
outcome in models adjusting for age at study entry and time from diagnosis to baseline 
questionnaire. All analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC).
Results
Among the 548 breast cancer survivors in our study, 270 (49.3 %) received endocrine 
therapy prior to study entry. The average age at enrollment was 58.1 years, with most ages at 
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diagnosis and study enrollment falling between 51 and 60 years (Table 1). Average age at 
diagnosis was 55.6 years. Among women with ER+ breast cancer who had not used 
endocrine therapy at the time of symptom assessment, 69.5 % initiated endocrine therapy 
after enrollment (n = 107) and 17.5 % had stage 0 disease, where endocrine therapy is less 
common due to variability in treatment strategies. Women with ER− breast cancer who had 
received endocrine therapy either had stage 0 (in situ) disease or PR+ tumors. The average 
time from breast cancer diagnosis to study entry was 2.6 years (SD = 3.3 years; range <1 to 
21).
Among the 468 women in the urinary incontinence analysis (Fig. 1), 86 (18.4 %) reported 
urinary incontinence symptoms. We observed no association between endocrine therapy and 
urinary incontinence overall (PR = 0.97; 95 % CI: 0.67, 1.43), or specific to use of 
tamoxifen (PR = 1.20; 95 % CI: 0.74, 1.96) or AIs (PR = 0.89; 95 % CI 0.55, 1.42), 
adjusting for age, time since diagnosis, race, parity, smoking status, hysterectomy history, 
and BMI (Table 2). In a sensitivity analysis restricting the study population to women with 
ER+ breast cancer, age-adjusted and multivariable prevalence ratios were similar to the 
overall estimates (data not shown). We also considered a more stringent definition of urinary 
incontinence that required leaking urine at least 2–3 times per week. With this definition, 
there were 54 cases of incontinence and the multivariable-adjusted PR for the association 
with endocrine therapy was 0.95 (95 % CI 0.57, 1.57). The majority of women who reported 
urinary incontinence had symptoms characteristic of both stress and urgency incontinence, 
also known as mixed incontinence (n = 44/86, 51.2 %). Therefore, sample sizes were 
insufficient to analyze stress or urgency incontinence alone. The prevalence ratios for 
urinary incontinence overall, any stress, or any urgency incontinence were suggestive of 
increased risk among tamoxifen users in age-adjusted models (PR = 1.37–1.82) but were 
attenuated after multivariable adjustment (PR = 1.20–1.67) and were not statistically 
significant. PRs for incontinence among AI users were generally closer to or below the null 
across incontinence definitions.
In our study population of women with a breast cancer diagnosis, 40–47 % reported no 
sexual activity in the last 30 days across domains of the SexFS questionnaire. Among those 
who were sexually active, there were no statistically significant differences according to 
endocrine therapy use across the domains of satisfaction, interest, vaginal discomfort, or 
lubrication. Mean scores showed slightly higher interest in sexual activity (45.4 vs. 44.0, p = 
0.08) and greater vaginal discomfort (44.8 vs. 42.8, p = 0.07) among women who used 
endocrine therapy compared to nonusers. However, differences were not large enough to 
exceed the minimally important difference for each domain (Table 3).
We further explored the relation between urinary incontinence and sexual function among 
women in our study. In age-adjusted models, urinary incontinence was significantly 
associated with lower scores in the satisfaction with sex life subdomain (p = 0.05), but not 
other sexual function domains. The proportion of women reporting no sexual activity was 
similar between women who did and did not experience urinary incontinence (43–44 %).
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Discussion
In our sample of women with early-stage breast cancer treated in the UNC Health Care 
system, we observed no overall difference in the prevalence of urinary incontinence or 
sexual dysfunction according to endocrine therapy use. The estrogenic response in pelvic 
floor tissues may vary between tamoxifen and AIs; however, no significant differences were 
observed for either type of endocrine therapy in our study population. These results provide 
reassuring evidence for women and providers that endocrine therapy may not substantially 
increase risk of urinary incontinence or sexual dysfunction after accounting for other factors 
including age, race, parity, or prior hysterectomy.
Our findings are consistent with a study conducted in postmenopausal breast cancer patients 
in Sweden, which detected no significant differences in urinary incontinence between 
endocrine therapy users and control subjects without treatment [19]. The Swedish study 
reported increased prevalence of sexual dysfunction symptoms associated with endocrine 
therapy, including vaginal dryness and pain with sexual intercourse. However, the 
comparison group consisted of women without breast cancer, [19] whereas our study 
compared endocrine therapy users to other women with breast cancer who did not use 
endocrine therapy.
Limited existing data suggest that the impact of estrogen on urinary incontinence varies 
based on whether estrogens are administered systemically (oral estrogens) or locally 
(vaginal estrogens) [13, 20, 21]. Oral menopausal hormone therapy with estrogen or 
estrogen plus progestin increased incidence of urinary incontinence after one year of 
treatment among participants in the Women’s Health Initiative trials (estrogen plus progestin 
trial RR 1.39, 95 % CI 1.27, 1.52; estrogen alone trial 1.53, 95 % CI 1.37, 1.71) [13], 
suggesting that increasing systemic estrogen levels may be associated with urinary 
incontinence. However, topical estrogens used locally have been associated with a reduction 
in incontinence for postmenopausal women [20]. Although not statistically significant, our 
estimates for AIs, which work by blocking estrogen synthesis, were in the direction of a 
decreased risk of urinary incontinence (PR 0.89, 95 % CI 0.55, 1.42). Additionally, the 
Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial showed a reduced incidence of 
urinary incontinence associated with anastrozole, an AI, as compared with tamoxifen (2 % 
versus 4 %) [22]. Our study population had a lower prevalence of urinary incontinence 
(18 %) than other similar studies of women with breast cancer, with estimates ranging from 
36 to 73 % [5, 19]; however, our population was also slightly younger (58.1 versus 62.7), not 
limited to postmenopausal women, and excluded preexisting urinary incontinence prior 
breast cancer diagnosis.
Our findings are consistent with a previous study that reported a minimal impact of 
endocrine therapy on sexual function [23]. Researchers evaluated sexual function before and 
after six months of endocrine therapy in a population of 66 postmenopausal women who had 
completed primary breast cancer therapy. Sexual function, as defined by lubrication, pain 
during intercourse, and sexual desire, arousal or satisfaction remained stable after endocrine 
therapy [23]. In an investigation of quality of life indicators during the first two years of the 
ATAC trial, tamoxifen users reported greater incidence of vaginal irritation, bleeding, or 
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spotting than AI users; however, AI users were more likely to report pain or discomfort with 
intercourse (AI 17.8 %, tamoxifen 7.5 %) and loss of interest in sex (AI 15.8 %, tamoxifen 
8.5 %) [7]. Though our results were not statistically significant, we observed differences in 
SexFS subdomain scores that suggest endocrine therapy users may have more trouble with 
vaginal discomfort and lubrication than nonusers, which is consistent with study results 
suggesting that both tamoxifen and AIs are associated with these effects [8, 19]. Vasomotor 
symptoms such as vaginal dryness appeared to be associated with both tamoxifen and AI use 
in our study and previous work [19].
Strengths of our analysis include a larger sample size to address these questions compared to 
prior reports [19, 23]. Extensive self-reported information was augmented by tumor and 
treatment information from medical records and prescription databases to obtain accurate 
information on endocrine therapy use and timing. Additionally, the PROMIS SexFS 
questionnaire has been previously validated in cancer patient populations to measure sexual 
function [16]. While the urinary incontinence assessment has not been previously validated, 
the prevalence of urinary incontinence in our sample was consistent with national averages 
for women over 50 in the general population [10].
Limitations of our analysis should also be considered. We did not have detailed information 
on the duration of endocrine therapy use or adherence to treatment. Additionally, women 
who were exposed to endocrine therapy were more likely to be further from diagnosis than 
those who were not (average time since diagnosis = 3.4 vs. 1.8 years, respectively). 
However, adjustment for years since diagnosis had minimal impact on multivariable model 
estimates. The majority of participants in our study were diagnosed with breast cancer 
within three years of study enrollment. Nearly half of our population reported no sexual 
activity in the last 30 days and, therefore, did not contribute to three of the four domain 
scores. This impacted our ability to look closely at the differences between tamoxifen and 
AI users. Sample sizes were also insufficient for stratified analyses of stress and urgency 
incontinence alone.
Urinary incontinence is a highly prevalent condition (≥15 %) among U.S. women over 50. In 
our study, the prevalence among women with a breast cancer diagnosis was similar and was 
associated with lower satisfaction scores on validated sexual function scales for women with 
a cancer diagnosis. Providers should be attentive to these symptoms whether or not 
endocrine therapy is recommended as part of the treatment plan.
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Fig. 1. 
Study flow chart for cohort selection for participants selected from the UNC Health 
Registry, August 2010–August 2015
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Table 1
Cohort characteristics, by endocrine therapy status and type of therapy (n = 548)
Characteristics No endocrine therapya
(n = 278)
Endocrine therapy
(n = 270)
Tamoxifen
(n = 107)
Aromatase inhibitors
(n = 131)
Age at enrollment
  18–40 18 (6.5) 6 (2.2) 5 (4.7) 0 (0.0)
  41–50 67 (24.1) 44 (16.3) 33 (30.8) 5 (3.8)
  51–60 89 (32.1) 81 (30.0) 44 (41.1) 28 (21.4)
  61–70 77 (27.7) 98 (36.3) 16 (15.0) 71 (54.2)
  70–88 27 (9.7) 41 (15.2) 9 (8.4) 27 (20.6)
Age at diagnosis
  18–40 28 (10.1) 15 (5.6) 11 (10.3) 0 (0.0)
  41–50 71 (25.5) 61 (22.6) 45 (42.1) 7 (5.3)
  51–60 93 (33.1) 87 (32.2) 35 (32.7) 43 (32.8)
  61–70 66 (23.7) 77 (28.5) 11 (10.3) 60 (45.8)
  70–85 21 (7.6) 30 (11.1) 5 (4.7) 21 (16.0)
Time since diagnosis
  0 to 1 year 181 (65.1) 61 (22.6) 22 (20.6) 36 (27.5)
  >1 to 2 years 28 (10.1) 65 (24.1) 24 (22.4) 38 (29.0)
  >2 to 3 years 18 (6.5) 36 (13.3) 16 (15.0) 18 (13.7)
  >3 to 21 years 51 (18.4) 108 (40.0) 45 (42.1) 39 (29.8)
Race
  White 196 (70.5) 220 (81.5) 83 (77.6) 110 (84.0)
  Black 68 (24.5) 35 (13.0) 18 (16.8) 16 (12.2)
  Other 14 (5.0) 15 (5.6) 6 (5.6) 5 (3.8)
Stage
  0 43 (15.5) 28 (10.4) 18 (16.8) 8 (6.1)
  1 104 (37.4) 122 (45.2) 34 (31.8) 75 (57.3)
  2 101 (36.3) 87 (32.2) 42 (39.3) 35 (26.7)
  3 30 (10.8) 33 (12.2) 13 (12.2) 13 (9.9)
Estrogen receptor test status
  Positive 154 (55.4) 259 (95.9) 100 (93.5) 128 (97.7)
  Negative 117 (42.1) 4 (1.5) 2 (1.9) 2 (1.5)
  Unknown 7 (2.5) 7 (2.6) 5 (4.7) 1 (0.8)
Received chemotherapy
  Yes 170 (64.4) 127 (47.0) 54 (49.5) 54 (41.2)
  No 99 (35.6) 143 (53.0) 53 (49.5) 77 (58.8)
Parity
  0 48 (17.3) 40 (14.8) 13 (9.9) 21 (19.6)
  1 or 2 152 (54.7) 154 (57.0) 75 (57.3) 64 (59.8)
  3–8 76 (27.3) 73 (27.0) 43 (32.8) 19 (17.8)
  Missing 2 (0.7) 3 (1.1) 0 (0.0) 3 (2.8)
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Characteristics No endocrine therapya
(n = 278)
Endocrine therapy
(n = 270)
Tamoxifen
(n = 107)
Aromatase inhibitors
(n = 131)
Smoking status
  Never 152 (54.7) 166 (61.5) 64 (59.8) 81 (61.8)
  Former 95 (34.2) 87 (32.2) 36 (33.6) 42 (32.1)
  Current 22 (7.9) 9 (3.3) 3 (2.8) 5 (3.8)
  Missing/do not know 9 (3.2) 8 (3.0) 4 (3.7) 3 (2.3)
Hysterectomy
  Yes 85 (30.6) 87 (32.2) 28 (26.2) 47 (35.9)
  No 193 (69.4) 183 (67.8) 79 (73.8) 84 (64.1)
Body mass index (kg/m2)
  <18.5 3 (1.1) 2 (0.7) 1 (0.9) 1 (0.8)
  18.5–24.9 90 (32.4) 88 (32.6) 40 (37.4) 35 (26.7)
  25.0–29.9 79 (28.4) 87 (32.2) 32 (29.9) 45 (34.4)
  >30.0 102 (36.7) 91 (33.7) 34 (31.8) 48 (36.6)
  Missing 4 (1.4) 2 (0.7) 0 (0.0) 2 (1.5)
a
Endocrine therapy is defined as receiving endocrine therapy prior to study entry. Women in the “no endocrine therapy” group may have later 
received endocrine therapy after completing the baseline questionnaire
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Table 3
Association of endocrine therapy with PROMIS sexual function and satisfaction measures domain scoresa
Domain n (%) Mean (SD) p value Minimally important
differenceb
Satisfaction: higher scores indicate more satisfaction with sex life
  Endocrine therapy 119 (44.1 %)c 54.5 (0.8) 0.90 4.2
  No endocrine therapy 111 (37.9 %)c 54.3 (0.8)
Interest: higher scores indicate more interest in sexual activity.
  Endocrine therapy 238 (88.1 %)d 45.4 (0.6) 0.08 4.5
  No endocrine therapy 233 (83.8 %)d 44.0 (0.6)
Vaginal discomfort: Higher scores indicate more discomfort.
  Endocrine therapy 114 (42.2 %)e 44.8 (0.8) 0.07 4.0
  No endocrine therapy 105 (37.8 %)e 42.8 (0.8)
Lubrication: higher scores indicate more lubrication.
  Endocrine therapy 115 (42.6 %)f 53.4 (0.8) 0.38 4.5
  No endocrine therapy 105 (37.9 %)f 54.5 (0.8)
aAdjusted for age at baseline and time from breast cancer diagnosis to study entry
b
Estimated as 0.5 × SD of the overall domain score means [18]
c121 (40.0 %) endocrine therapy users and 122 (44.8 %) nonusers reported no sexual activity in the last 30 days. 30 (11.1 %) endocrine therapy 
users and 45 (16.2 %) nonusers did not respond to questions comprising the satisfaction domain
d32 (11.9 %) of endocrine therapy users and 45 (16.2 %) nonusers did not respond to questions comprising the interest domain. There were no non-
applicable response options for this domain
e127 (47.0 %) endocrine therapy users and 126 (45.3 %) nonusers reported no sexual activity in the last 30 days. 29 (10.7 %) endocrine therapy 
users and 46 (16.5 %) nonusers did not respond to questions comprising the vaginal discomfort domain
f124 (45.9 %) endocrine therapy users and 127 (45.7 %) nonusers reported no sexual activity in the last 30 days. 31 (11.5 %) endocrine therapy 
users and 46 (16.5 %) nonusers did not respond to questions comprising the vaginal discomfort domain
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